Volume 5, Supplement 1SupplementNew Advances in the Treatment of Hypogonadism in the Aging MaleChristopher P SteidleTestosterone replacement therapyHypogonadismErectile dysfunctionOsteoporosisAndropause syndrome
Volume 6, Supplement 6SupplementOsteopenia and Male HypogonadismAdrian DobsKendall DupreeTestosteroneHypogonadismOsteoporosisBone mineral density
Volume 7, Supplement 3Review ArticlesSelective Estrogen Receptor Modulators to Prevent Treatment-Related OsteoporosisMatthew R SmithProstate cancerOsteoporosisToremifeneBone mineral densityGonadotropin-releasing hormone agonistsRaloxifene
Volume 11, Number 4Review ArticlesThe Impact of Prostate Cancer and Hormonal Therapy on BoneManagement ReviewGerald L AndrioleLarge-scale studies agree that the observed decline in prostate cancer mortality that began in the early 1990s, shortly after prostate-specific antigen testing was introduced in the United States, is most likely explained by more widespread treatment of prostate cancer, including hormonal therapy. Practitioners should be aware of the risk of the development of osteoporosis and of skeletal side effects related to hormonal therapy to optimize the care of men with prostate cancer.[Rev Urol. 2009;11(4):185-189 doi: 10.3909/riu0469]© 2009 MedReviews®, LLCAndrogen deprivation therapyHormone deprivation therapyBonedestructionOsteoporosisOsteopenia